ICG fluorescence guided intraoperative lymph node detection and management in breast cancer

Clinical application of intraoperative lymph node detection and management of breast cancer based on ICG fluorescence guidance

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022138

Enrollment

Unknown

Registered

2019-03-26

Start date

2019-04-08

Completion date

Unknown

Last updated

2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

ICG Group:ICG injection+Methylene blue injection

Control group:Methylene blue injection

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Aged 18 to 70 years; ? Able to understand the status of this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: ? Pregnant or lactating patients; ? Severe allergy history or ICG/iodine allergy; ? Axillary surgery or chemoradiotherapy history.

Design outcomes

Primary

Measure	Time frame
Sentinel lymph node detection rate;Lymph node metastasis rate;Survival rate;Adverse reaction rate;	—

Countries

China

Contacts

Public ContactXiangming Fang

xiangming_fang@njum.edu.com+86 13861779030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026